At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Single and Multiple Doses of Pirtobrutinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating Rosuvastatin and Pirtobrutinib for Healthy. Completed, enrolled 32 participants across 2 sites.
Detailed Summary
The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with pirtobrutinib in healthy participants. This study will last up to approximately 26 days excluding screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartJan 2022
Primary CompletionApr 2022
TodayJul 2026
First PostedJan 4, 2022
Enrollment StartJan 11, 2022
Primary CompletionApr 20, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.5 years ago
Interventions
Rosuvastatindrug
Administered Orally.
Pirtobrutinibdrug
Administered Orally.